Study of short-acting, long-acting and abuse-deterrent opioid use
The mix of opioids is crucial to the cost impact of abuse-deterrent opioidsNovember 30, 2017
What was the study about?
With opioid use and abuse continuing to rise, plan sponsors need to use every tool at their disposal. Prime continues to identify valuable insights from years of pharmacy and medical analysis expertise.
This study looked at medical and pharmacy claims to define and divide utilization patterns, quantities, dosages and diagnoses into three separate groups:
- Members who were only prescribed short-acting opioids
- Members who were only prescribed long-acting opioids
- Members who were prescribed both short- and long-acting opioids
What did we learn?
Most members who get opioids are prescribed short-acting opioids. And most of them have only one or two claims. That is consistent with prescribing guidelines.
But groups of members exist that appear to be experiencing non-typical opioid prescribing. This gives a plan sponsor thousands of members where they might intervene to improve health outcomes and increase savings.
We identified more than 1 million members (9 percent) who had at least one opioid claim (out of 12 million continuously enrolled from July 1, 2013 to Sept. 1, 2014). These members were divided into the three groups identified above. The groups were followed for 12 months. Medical claims were used to further divide them by diagnosis.
Short-acting only: 94 percent (of the 9 percent) were prescribed short-acting opioids. As would be expected, nearly two thirds of these members received only one or two prescriptions. 66 percent of members received only one prescription with less than 10 pills. But 6 percent of members had 16 or more claims within 12 months. This indicates the use of short-acting opioids for long-term chronic opioid therapy.
Long-acting: Only 1 percent (of the 1 million opioid utilizers) were prescribed long-acting opioids. Just over half of these members received only one or two prescriptions. 62 percent of these members were new starts – they had no claims for opioids in the previous 120 days. It is unsafe to initiate opioid therapy with a long-acting opioid. The CDC recommends against it. 9 percent of these members had 16 or more claims within 12 months. These members are on chronic opioid therapy with only long-acting opioids. Long-acting opioid therapy should always include a short-acting opioid for break through pain. It is not recommended to be on long-acting opioid therapy only. These all represent opportunities for interventions.
Short- and long-acting: 6 percent (of the 1 million) were prescribed both short- and long-acting opioids. 54 percent of these members had 16 or more claims within 12 months. 4 percent of these members had a cancer diagnosis.
Diagnoses: Most common diagnoses for all three groups were: low back pain, joint pain and arthritis, followed by abdominal pain and headache. Percentages varied for each. The study poster includes more detail. The CDC recommends avoiding opioids for the treatment of back pain and headache.
GuidedHealth® interventions can target:
- Long-acting opioid utilizers
- Members with a large quantity of opioids in a short period of time
- Members without evidence of diagnosis
- A prior authorization (PA) program could help address opioid use patterns among large numbers of new starts. Potential savings for a new start PA could save $0.01 per member per month.
Additional research could focus on short- vs long-term use, and concurrent treatments – like use of benzodiazepines and opioid prescriptions.
What does this mean for you?
Prime’s Controlled Substance Management Program can help plan sponsors identify members with a variety of risk profiles, using specific claim analyses and predictive models. A range of clinical and outreach programs are available to help plan sponsors achieve savings, quality and outcomes goals.
March 30, 2023
Drug oversupply, or stockpiling, due to overlapping drug refills can cause unnecessary drug costs
If you have a chronic condition, your pharmacy may notify you advance of…
March 28, 2023
Biosimilars are at the door, Part 3
News about biosimilars is everywhere. Sometimes you just need the basics. This four-part…
March 27, 2023
Specialty Drug Pipeline Update: March 2023
This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…